

PHOENIX CLINICAL TRIALS

Breast Cancer

COMETI CTC HR+ mBreast Cancer

Characterization of Circulating Tumor Cells from Subjects with Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index

AI+Everolimus Stomatitis Prophylaxis

Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis

B47 Chemo+\-Trastuz HER2low Adj Breast

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Niraparib vs PhyChice HER2-gBRCA Breast

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-Treated, Her2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

LY2835219(CDK4/6inh) 3rdIn HR+HER2- MBC

A Phase II Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Rd Ph2 Lucitanib FGF Aberrant MBC

A Phase II, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer

MM302+Trast vs TPC HER2+ MBC

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

Trast+-Pertuzumab TDMIpretreatHer2+MBC

A Phase II - Her2-Overexpressing Metastatic Breast Cancer, Physicians Choice Plus Trastuzumab Plus Pertuzimab vs Physicians Choice Plus Trastuzumab

Cervical Cancer

Adj Chemo vs Chemorad for Cervical Ca

A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial

Gynecologic Cancer

Trabectedin +/- PLD Adv Ovarian 2/3 In

A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Leukemia

CML Observational Trial - SIMPLICITY

Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)

Azacitidine+BSC vs BSC AML Remission

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Moxetumomab Pasudotox R/R HCL

A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

Idela + Ritux, ILn CLL, I7p Del

A Phase II, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

Lung Cancer

Nivolumab for Sqm or Non-Sqm NSCLC

A Phase IIIb/IV Safety Trial of Nivolumab in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

BMS Non-Interventional Stg4 NSCLC & SCLC

Lung Cancer Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

For more information or to refer a patient, call 888-972-CURE.



Lung Cancer Continued

LDK378 v SOC ALK+ NSCLC post Chemo/Criz
A Phase III, Multicenter, Randomized, Open-Label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients with ALK-Rearranged (ALK-Positive) Advanced Non-Small Cell Lung Cancer Who Have Been Treated Previously with Chemotherapy (Platinum Doublet) and Crizotinib

Lymphomas

CD30 Screening in Solid Tumors and NHL
Screening Protocol to Detect Tumor Antigen Expression Required for Enrollment on Clinical Research Protocols of Antibody-Directed Therapy

Myeloma

Daratumumab-Rd vs Rd in R/R MM (POLLUX)
Phase III Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed or Refractory Multiple Myeloma

Nausea/Vomiting

APF530+Placebo v Zofran+placebo CINV HEC
A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase III Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Subjects Receiving Highly Emetogenic Chemotherapy

Ovarian Cancer

Ph2 DNIB0600A vs Doxorubicin Plat Resist Ovarian
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer

Pancreatic Cancer

Ph3 Jak Inhibitor w Cape for mPC
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor, Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or are Intolerant to First-Line Chemotherapy

Renal Cancer

PRINCIPAL Obs Study of Pazopanib in RCC
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib

Solid Tumors/Hematologic

Signature Series: CDK4/6 Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 8 - LEE011 for Patients with CDK4/6 Pathway Activated Tumors

Signature Series: BCJ398 FGFR Alteration
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 6 - BGJ398 for Patients with Tumors with FGFR Genetic Alterations

Signature Series: LDK378 ALK ROS1 Aberrations
Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) For Patients Whose Tumors Have Aberrations in ALK or ROS1

